About Celecure News Pipeline Our Team Partnering with Celecure Careers at Celecure Contact	News 10.01.07Celecure receives 1.6 million euros from four founders of Skype Investment group Ambient Sound Investments (ASI) has agreed to invest 1.6 million euros in Estonian biotechnology drug developer Celecure to accelerate the international breakthrough of its projects. 21.11.06Celecure Group opened Cancer Clinic 15.10.06Celecure will attend annual partnering forum BioEurope 2006 Celecure will attend the BioEurope 2006 partnering forum in Duesseldorf, Germany to present the the latest data about it´s anti-angiogenesis compound SB101. 30.03.06Minister of European Affairs of Republic of France visits Celecure 05.03.05Celecure has filed national patents for SB101 Celecure has filed national patent applications for SB101 in US, EU, Canada, Australia, Japan, China, and India. 02.01.05Celecure moves into new premises Celecure Group has moved into its new laboratory and office space in the Life Science campus of Tallinn University of Technology. 12.11.04Celecure signs licensing deal with Angitia AB Swedish company Angitia AB and Estonian company Celecure AS sign a worldwide licensing agreement for a novel angiogenesis inhibitor for treatment of cancer.
Celecure ASAkadeemia 15, 12618 Tallinn, Estoniatel +372 6204350info@celecure.com